ALNY
Alnylam Pharmaceuticals, Inc.
170.08
USD
This page is just a preview of the data found in TrendSpider’s full version
Alnylam Pharmaceuticals, Inc. stock is up 5.06% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 19 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 CALLs, 7 PUTs. 50% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 29 Nov 17:56 | 19 Apr, 2024 | 155.00 | 24 | ||
| 29 Nov 17:56 | 19 Apr, 2024 | 125.00 | 145 | ||
| 29 Nov 17:56 | 19 Apr, 2024 | 125.00 | 145 | ||
| 29 Nov 17:57 | 19 Apr, 2024 | 130.00 | 818 | ||
| 30 Nov 15:25 | 15 Dec, 2023 | 170.00 | 1282 | ||
| 30 Nov 16:01 | 15 Dec, 2023 | 145.00 | 154 | ||
| 04 Dec 18:42 | 21 Jun, 2024 | 210.00 | 203 | ||
| 04 Dec 18:42 | 21 Jun, 2024 | 210.00 | 203 | ||
| 04 Dec 18:43 | 21 Jun, 2024 | 210.00 | 203 | ||
| 04 Dec 20:04 | 19 Apr, 2024 | 150.00 | 246 |
Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
